Kyung Nam Pharm Statistics

Total Valuation

Kyung Nam Pharm has a market cap or net worth of KRW 50.48 billion. The enterprise value is 37.26 billion.

Market Cap	50.48B
Enterprise Value	37.26B

Important Dates

The last earnings date was Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Kyung Nam Pharm has 78.15 million shares outstanding. The number of shares has increased by 22.60% in one year.

Current Share Class	n/a
Shares Outstanding	78.15M
Shares Change (YoY)	+22.60%
Shares Change (QoQ)	+88.45%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	42.39M

Valuation Ratios

The trailing PE ratio is 5.01.

PE Ratio	5.01
Forward PE	n/a
PS Ratio	0.46
PB Ratio	0.44
P/TBV Ratio	0.44
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.93, with an EV/FCF ratio of -8.01.

EV / Earnings	3.70
EV / Sales	0.61
EV / EBITDA	15.93
EV / EBIT	n/a
EV / FCF	-8.01

Financial Position

The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.33.

Current Ratio	1.68
Quick Ratio	1.40
Debt / Equity	0.33
Debt / EBITDA	16.84
Debt / FCF	-8.08
Interest Coverage	-0.12

Financial Efficiency

Return on equity (ROE) is -3.98% and return on invested capital (ROIC) is -0.10%.

Return on Equity (ROE)	-3.98%
Return on Assets (ROA)	-0.09%
Return on Invested Capital (ROIC)	-0.10%
Return on Capital Employed (ROCE)	-0.20%
Revenue Per Employee	265.47M
Profits Per Employee	44.00M
Employee Count	229
Asset Turnover	0.36
Inventory Turnover	3.39

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -50.65% in the last 52 weeks. The beta is 0.20, so Kyung Nam Pharm's price volatility has been lower than the market average.

Beta (5Y)	0.20
52-Week Price Change	-50.65%
50-Day Moving Average	672.46
200-Day Moving Average	843.94
Relative Strength Index (RSI)	48.77
Average Volume (20 Days)	385,088

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kyung Nam Pharm had revenue of KRW 60.79 billion and earned 10.08 billion in profits. Earnings per share was 198.77.

Revenue	60.79B
Gross Profit	17.23B
Operating Income	-242.82M
Pretax Income	-3.22B
Net Income	10.08B
EBITDA	2.23B
EBIT	-242.82M
Earnings Per Share (EPS)	198.77

Full Income Statement

Balance Sheet

The company has 50.81 billion in cash and 37.59 billion in debt, giving a net cash position of 13.23 billion or 169.27 per share.

Cash & Cash Equivalents	50.81B
Total Debt	37.59B
Net Cash	13.23B
Net Cash Per Share	169.27
Equity (Book Value)	115.22B
Book Value Per Share	1,474.44
Working Capital	31.55B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.84 billion and capital expenditures -6.49 billion, giving a free cash flow of -4.65 billion.

Operating Cash Flow	1.84B
Capital Expenditures	-6.49B
Free Cash Flow	-4.65B
FCF Per Share	-59.53

Full Cash Flow Statement

Margins

Gross margin is 28.33%, with operating and profit margins of -0.40% and 16.58%.

Gross Margin	28.33%
Operating Margin	-0.40%
Pretax Margin	-5.30%
Profit Margin	16.58%
EBITDA Margin	3.67%
EBIT Margin	-0.40%
FCF Margin	n/a

Dividends & Yields

Kyung Nam Pharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.60%
Shareholder Yield	-22.60%
Earnings Yield	19.96%
FCF Yield	-9.22%

Stock Splits

The last stock split was on December 13, 2013. It was a reverse split with a ratio of 0.2.

Last Split Date	Dec 13, 2013
Split Type	Reverse
Split Ratio	0.2

Scores

Kyung Nam Pharm has an Altman Z-Score of 0.79. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.79
Piotroski F-Score	n/a